Status:
COMPLETED
SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with conventional stepwise treatment according to asthma treatment guidelines in patients with persistent asthma.
Eligibility Criteria
Inclusion
- Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition. Prescribed inhaled GCS at a dose of ³400 µg/day and within the approved label for the relevant drug during the last 3 months prior to Visit 1.
Exclusion
- Use of any b-blocking agent, including eye-drops, Use of oral GCS as maintenance treatment, A history of smoking ³ 10 pack years (1 pack year = 1 pack (20 cigarettes) per day for one year or equivalent).
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00259792
Start Date
September 1 2004
End Date
January 1 2006
Last Update
January 24 2011
Active Locations (82)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Abbeville, France
2
Research Site
Agen, France
3
Research Site
Ajaccio, France
4
Research Site
Albi, France